Hepatocellular Carcinoma - Pipeline Review, H1 2017

  • ID: 4311846
  • Report
  • 1014 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Can-Fite BioPharma Ltd
  • Genoscience Pharma
  • InteRNA Technologies BV
  • NovaTarg Therapeutics Inc
  • Regulus Therapeutics Inc
  • MORE
Hepatocellular Carcinoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 78, 46, 3, 70, 14 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 10, 4, 1, 28 and 1 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Can-Fite BioPharma Ltd
  • Genoscience Pharma
  • InteRNA Technologies BV
  • NovaTarg Therapeutics Inc
  • Regulus Therapeutics Inc
  • MORE
  1. Introduction
  2. Hepatocellular Carcinoma - Overview
  3. Hepatocellular Carcinoma - Therapeutics Development
  4. Hepatocellular Carcinoma - Therapeutics Assessment
  5. Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  6. Hepatocellular Carcinoma - Drug Profiles
  7. Hepatocellular Carcinoma - Dormant Projects
  8. Hepatocellular Carcinoma - Discontinued Products
  9. Hepatocellular Carcinoma - Product Development Milestones
  10. Appendix
List of Tables:
  1. Number of Products under Development for Hepatocellular Carcinoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Companies, H1 2017 (Contd..2), H1
  5. Number of Products under Development by Companies, H1 2017 (Contd..3), H1
  6. Number of Products under Development by Companies, H1 2017 (Contd..4), H1
  7. Number of Products under Development by Companies, H1 2017 (Contd..5), H1
  8. Number of Products under Development by Companies, H1 2017 (Contd..6), H1
  9. Number of Products under Development by Companies, H1 2017 (Contd..7), H1
  10. Number of Products under Development by Companies, H1 2017 (Contd..8), H1
  11. Number of Products under Development by Universities/Institutes, H1
  12. Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  13. Products under Development by Companies, H1
  14. Products under Development by Companies, H1 2017 (Contd..1), H1
  15. Products under Development by Companies, H1 2017 (Contd..2), H1
  16. Products under Development by Companies, H1 2017 (Contd..3), H1
  17. Products under Development by Companies, H1 2017 (Contd..4), H1
  18. Products under Development by Companies, H1 2017 (Contd..5), H1
  19. Products under Development by Companies, H1 2017 (Contd..6), H1
  20. Products under Development by Companies, H1 2017 (Contd..7), H1
  21. Products under Development by Companies, H1 2017 (Contd..8), H1
  22. Products under Development by Companies, H1 2017 (Contd..9), H1
  23. Products under Development by Companies, H1 2017 (Contd..10), H1
  24. Products under Development by Companies, H1 2017 (Contd..11), H1
  25. Products under Development by Companies, H1 2017 (Contd..12), H1
  26. Products under Development by Companies, H1 2017 (Contd..13), H1
  27. Products under Development by Universities/Institutes, H1
  28. Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
  29. Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1
  30. Number of Products by Stage and Target, H1
  31. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  32. Number of Products by Stage and Target, H1 2017 (Contd..2), H1
  33. Number of Products by Stage and Target, H1 2017 (Contd..3), H1
  34. Number of Products by Stage and Target, H1 2017 (Contd..4), H1
  35. Number of Products by Stage and Target, H1 2017 (Contd..5), H1
  36. Number of Products by Stage and Target, H1 2017 (Contd..6), H1
  37. Number of Products by Stage and Mechanism of Action, H1
  38. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  39. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1
  40. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1
  41. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1
  42. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1
  43. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1
  44. Number of Products by Stage and Route of Administration, H1
  45. Number of Products by Stage and Molecule Type, H1
  46. Hepatocellular Carcinoma - Pipeline by AB Science SA, H1
  47. Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1
  48. Hepatocellular Carcinoma - Pipeline by Abivax SA, H1
  49. Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H1
  50. Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1
  51. Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1
  52. Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H1
  53. Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1
  54. Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1
  55. Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1
  56. Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1
  57. Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1
  58. Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1
  59. Hepatocellular Carcinoma - Pipeline by Bayer AG, H1
  60. Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1
  61. Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1
  62. Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1
  63. Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1
  64. Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1
  65. Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1
  66. Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1
  67. Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1
  68. Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1
  69. Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1
  70. Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1
  71. Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1
  72. Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1
  73. Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H1
  74. Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1
  75. Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1
  76. Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1
  77. Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1
  78. Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1
  79. Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H1
  80. Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1
  81. Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1
  82. Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1
  83. Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1
  84. Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H1
  85. Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H1
  86. Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1
  87. Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H1
  88. Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1
  89. Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1
  90. Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1
  91. Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1
  92. Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1
  93. Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1
  94. Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1
  95. Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1
  96. Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1
  97. Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1
  98. Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H1
  99. Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H1
  100. Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1
  101. Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H1
  102. Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1
  103. Hepatocellular Carcinoma - Pipeline by Humorigin Biotechnology Corp, H1
  104. Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1
  105. Hepatocellular Carcinoma - Pipeline by Immune Therapeutics Inc, H1
  106. Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1
  107. Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1
  108. Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1
  109. Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H1
  110. Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H1
  111. Hepatocellular Carcinoma - Pipeline by Incyte Corp, H1
  112. Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H1
  113. Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H1
  114. Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H1
  115. Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H1
  116. Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1
  117. Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H1
  118. Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H1
  119. Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H1
  120. Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H1
  121. Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H1
  122. Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H1
  123. Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H1
  124. Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H1
  125. Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H1
  126. Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H1
  127. Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H1
  128. Hepatocellular Carcinoma - Pipeline by Medivir AB, H1
  129. Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H1
  130. Hepatocellular Carcinoma - Pipeline by Merck KGaA, H1
  131. Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H1
  132. Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H1
  133. Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H1
  134. Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H1
  135. Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H1
  136. Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H1
  137. Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H1
  138. Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H1
  139. Hepatocellular Carcinoma - Pipeline by Novartis AG, H1
  140. Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H1
  141. Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H1
  142. Hepatocellular Carcinoma - Pipeline by Omeros Corp, H1
  143. Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H1
  144. Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H1
  145. Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H1
  146. Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H1
  147. Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H1
  148. Hepatocellular Carcinoma - Pipeline by Onxeo SA, H1
  149. Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H1
  150. Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H1
  151. Hepatocellular Carcinoma - Pipeline by PepVax Inc, H1
  152. Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H1
  153. Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H1
  154. Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H1
  155. Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H1
  156. Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H1
  157. Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H1
  158. Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H1
  159. Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H1
  160. Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H1
  161. Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H1
  162. Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H1
  163. Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H1
  164. Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H1
  165. Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H1
  166. Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1
  167. Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H1
  168. Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Company Ltd, H1
  169. Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H1
  170. Hepatocellular Carcinoma - Pipeline by tella Inc, H1
  171. Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H1
  172. Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H1
  173. Hepatocellular Carcinoma - Pipeline by Theravectys SA, H1
  174. Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H1
  175. Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H1
  176. Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H1
  177. Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H1
  178. Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H1
  179. Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H1
  180. Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H1
  181. Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H1
  182. Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H1
  183. Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H1
  184. Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H1
  185. Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H1
  186. Hepatocellular Carcinoma - Dormant Projects, H1
  187. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..1), H1
  188. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..2), H1
  189. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..3), H1
  190. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..4), H1
  191. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..5), H1
  192. Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..6), H1
  193. Hepatocellular Carcinoma - Discontinued Products, H1
  194. Hepatocellular Carcinoma - Discontinued Products, H1 2017 (Contd..1), H1
  195. Hepatocellular Carcinoma - Discontinued Products, H1 2017 (Contd..2), H1
List of Figures:
  1. Number of Products under Development for Hepatocellular Carcinoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Top 10 Routes of Administration, H1
  9. Number of Products by Stage and Top 10 Routes of Administration, H1
  10. Number of Products by Top 10 Molecule Types, H1
  11. Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • Abivax SA
  • Acceleron Pharma Inc
  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories LLC
  • Alfact Innovation
  • Amgen Inc
  • AndroScience Corp
  • ArQule Inc
  • Array BioPharma Inc
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • Bio-Cancer Treatment International Ltd
  • Biomics Biotechnologies Co Ltd
  • Bioneer Corp
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd
  • CASI Pharmaceuticals Inc
  • CBT Pharmaceuticals Inc
  • CCRP Therapeutics GmbH
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celsion Corp
  • China Medical System Holdings Ltd
  • Chugai Pharmaceutical Co Ltd
  • Conatus Pharmaceuticals Inc
  • Delcath Systems Inc
  • Dicerna Pharmaceuticals Inc
  • Double Bond Pharmaceutical International AB
  • eFFECTOR Therapeutics Inc
  • Eiger BioPharmaceuticals Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Endocyte Inc
  • Epeius Biotechnologies Corp
  • eTheRNA Immunotherapies NV
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Galaxy Biotech LLC
  • Genelux Corp
  • Genoscience Pharma
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp
  • Green Cross Cell Corp
  • Green Cross Corp
  • H3 Biomedicine Inc
  • HanAll Biopharma Co Ltd
  • Horizon Pharma Plc
  • Humorigin Biotechnology Corp
  • Immatics Biotechnologies GmbH
  • Immune Therapeutics Inc
  • Immunicum AB
  • Immunitor Inc
  • Immunomedics Inc
  • Immunovative Therapies Ltd
  • In-Cell-Art SAS
  • Incyte Corp
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • InteRNA Technologies BV
  • Jenrin Discovery Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • KAHR medical Ltd
  • Karcinolys SAS
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Kowa Company Ltd
  • Les Laboratoires Servier SAS
  • Ligand Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • MaxCyte Inc
  • MedImmune LLC
  • Medivir AB
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Midatech Pharma Plc
  • Millennium Pharmaceuticals Inc
  • Mina Therapeutics Ltd
  • MTG Biotherapeutics Inc
  • MultiCell Technologies Inc
  • NeuroVive Pharmaceutical AB
  • NormOxys Inc
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Nymox Pharmaceutical Corp
  • Omeros Corp
  • Oncolys BioPharma Inc
  • OncoMed Pharmaceuticals Inc
  • OncoTherapy Science Inc
  • Oneness Biotech Co Ltd
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Otsuka Holdings Co Ltd
  • Panacea Pharmaceuticals Inc
  • PepVax Inc
  • Peregrine Pharmaceuticals Inc
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • PharmaEssentia Corp
  • Provecs Medical GmbH
  • Provectus Biopharmaceuticals Inc
  • Q BioMed Inc
  • RedHill Biopharma Ltd
  • Regulus Therapeutics Inc
  • Saronic Biotechnology Inc
  • Shenogen Pharma Group Ltd
  • Sillajen Biotherapeutics
  • Simcere Pharmaceutical Group
  • Sun Pharma Advanced Research Company Ltd
  • Taiwan Liposome Company Ltd
  • Takeda Pharmaceutical Company Ltd
  • TC BioPharm Ltd
  • tella Inc
  • Tessa Therapeutics Pte Ltd
  • Therapure Biopharma Inc
  • Theravectys SA
  • Threshold Pharmaceuticals Inc
  • Tiziana Life Sciences Plc
  • TRACON Pharmaceuticals Inc
  • Tumorend LLC
  • UbiVac LLC
  • VasGene Therapeutics Inc
  • Vaxon Biotech
  • Vect-Horus SAS
  • Verlyx Pharma Inc
  • VG Life Sciences Inc
  • Vicus Therapeutics LLC
  • Yooyoung Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll